Phase I study evaluating combination therapy with the receptor tyrosine kinase inhibitor PLX3397 and Sirolimus in patients with unresectable sarcoma and Phase II study in malignant peripheral nerve sheath tumors
A Study for Patients with Malignant Peripheral Nerve Sheath Tumors Using Study Drugs PLX3397 and Sirolimus
Sponsor: Plexxikon and FDA
Enrolling: Male and Female Patients
IRB Number: AAAO6059
U.S. Govt. ID: NCT02584647
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine if treatment with PLX3397 and Sirolimus will be tolerated and result in shrinking of the cancer or stopping the cancer from growing. In the phase I portion, the maximum tolerated dose of the study drug will be determined. In the phase II portion, progression-free survival will be assessed at the dose level found in Phase I. Participants will continue to take study drug until they experience an unacceptable side effect or their disease progresses.
Investigator
Gulam Manji, MD, PhD
Do You Qualify?
Do you have a confirmed diagnosis of malignant peripheral nerve sheath tumors (MPNSTs)? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162